Compound with anti-psoriasis activity and application thereof

By developing JAK/HDAC dual-target inhibitor compounds Z17j and Z17h, the existing psoriasis treatment has been solved, and excellent anti-psoria activity and anti-inflammatory effects have been achieved in vitro and in vivo.

CN119039276APending Publication Date: 2024-11-29THE NAVAL MEDICAL UNIV OF PLA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410987944.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing psoriasis treatment methods have poor efficacy and adverse reactions, and single-target drugs have limited effects when facing complex diseases, and lack effective multi-target treatment strategies.

Method used

A class of JAK/HDAC dual-target inhibitor compounds Z17j and Z17h with anti-psoria activity were developed to inhibit JAK and HDAC enzyme activities in vitro and demonstrate good anti-inflammatory and anti-psorblasts in mouse models in vivo disease activity is better than its parent drug and combined dosing group.

Benefits of technology

Compounds Z17j and Z17h showed excellent anti-psoria activity in in vitro and in vivo experiments, had minor side effects, and their anti-inflammatory effects were better than existing representative targeted preparations, showing good efficacy and safety. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039276A_ABST
    Figure CN119039276A_ABST
Patent Text Reader

Abstract

The invention discloses a compound with anti-psoriasis activity or a pharmaceutical salt thereof, and the structural general formula of the compound is as follows: # imgabs0. The compound with anti-psoriasis activity provided by the invention has good efficacy on various in-vitro anti-psoriasis related tests and in-vivo imiquimod induced mouse models; the compound Z17h and the compound Z17j show better anti-psoriasis activity than their parent drugs and combined administration of the parent drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a class of compounds with anti-psoriasis activity and applications thereof. Background Art

[0002] Psoriasis, also known as psoriasis, is a chronic inflammatory skin disease caused by systemic immune abnormalities induced by multiple genetic inheritance and multiple environmental factors. Its occurrence is related to the body's immunity and affects 2% to 3% of the world's population. It is characterized by excessive proliferation of keratinocytes, the appearance of red or brown maculopapules or plaques, and the surface is covered with white scales, usually affecting the skin, and has been shown to involve different organ systems and is associated with a variety of diseases.

[0003] Traditional treatments for psoriasis mainly include local treatment and systemic treatment, including some hormone drugs, methotrexate, and the combination of multiple drugs. There are problems such as poor efficacy and adverse reactions. Therefore, new treatments for psoriasis are urgently needed in clinical practice. For a long time, the treatment of psoriasis has relied on nonspecific anti-inflammatory drugs and immunosuppressants, and related research on targeted drugs has provided new strategies for the treatment of psoriasis. Currently, the representative targeted preparations for the treatment of psoriasis in clinical practice, JAK inhibitors, such as tofacitinib and deucravacitinib, are used to treat plaque psoriasis and psoriatic arthritis. There are also other targeted preparations for psoriasis research, such as HDAC inhibitors. Studies have shown that HDAC may be involved in the pathogenesis of psoriasis. Domestic and foreign studies have found that both targeted preparations have excellent anti-inflammatory activity and have been used in various inflammatory diseases.

[0004] Single-target drugs often have difficulty achieving the desired effect when facing complex diseases, such as autoimmune diseases and tumors, while multi-target drugs regulate multiple pathways to achieve therapeutic goals while having fewer side effects. The emergence of single-molecule multi-target inhibitors provides a new strategy for improving drug efficacy and exerting synergistic effects, and can avoid drug-drug interactions and reduce toxicity. Therefore, the development of multi-target strategies provides a reference for the further development of JAK inhibitors. As a class of multi-target inhibitors, JAK / HDAC inhibitors are used to treat hematological malignancies and solid cancers, and may also overcome drug resistance caused by the tumor microenvironment. There are currently no reports on the use of JAK / HDAC inhibitors in the treatment of psoriasis, but the synergistic anti-inflammatory effects of JAK / HDAC dual-target inhibitors may provide a new method with high efficiency and few side effects for the treatment of psoriasis. Summary of the invention

[0005] The first object of the present invention is to provide a class of compounds having anti-psoriasis activity.

[0006] The second object of the present invention is to provide a use of the compound having anti-psoriatic activity in the preparation of anti-psoriatic drugs.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0008] In the first aspect of the present invention, a class of compounds having anti-psoriatic activity or pharmaceutically acceptable salts thereof are provided, and the general structural formula is shown below:

[0009]

[0010] Wherein, R1 is selected from one of the following structures:

[0011]

[0012] R2 is selected from one of the following structures:

[0013]

[0014] R3 is selected from OH, n1 is a positive integer selected from 0 to 10 (preferably 0, 1, 2, 3, 4, 5);

[0015] n2 is a positive integer selected from 0 to 10 (preferably 0, 1, 2, 3, 4, 5);

[0016] m1 is selected from a positive integer of 0 to 20 (preferably 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10); m2 is selected from a positive integer of 0 to 20 (preferably 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10); R4 is selected from H, NH2, R5 is selected from H, NH2, R6 is selected from H, NH2, R7 is selected from H, NH2, R8 is selected from H, NH2, R9 is selected from H, C1-C20 alkyl;

[0017] R 10 Selected from H, C1-C20 alkyl.

[0018] Preferably, in the compound having anti-psoriasis activity, R1 is selected from one of the following structures:

[0019]

[0020] R2 is selected from one of the following structures:

[0021]

[0022] Most preferably, the compound having anti-psoriatic activity is selected from one of the following structures:

[0023]

[0024]

[0025] The pharmaceutically acceptable salt is an acid addition salt formed by the compound having anti-psoriatic activity and the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, tartaric acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid.

[0026] The second aspect of the present invention provides a use of the compound having anti-psoriatic activity or a pharmaceutically acceptable salt thereof in the preparation of an anti-psoriatic drug.

[0027] The third aspect of the present invention provides a use of the compound having anti-psoriasis activity or a pharmaceutically acceptable salt thereof in the preparation of an anti-inflammatory drug.

[0028] The fourth aspect of the present invention provides a use of the compound having anti-psoriasis activity or a pharmaceutically acceptable salt thereof in the preparation of a JAK / HDAC dual-target inhibitor.

[0029] The compounds of the present invention exhibit good in vitro inhibition of JAK and HDAC enzyme activity. The results of in vitro inhibition of NO release from RAW264.7 cells, inhibition of TNF-α-induced HaCat cell proliferation experiments, and anti-imiquimod-induced mouse psoriasis experiments showed that compounds Z17j and Z17h are JAK / HDAC dual-target inhibitors, have good anti-inflammatory and anti-psoriatic activities, and are superior to their parent compounds (CYT387, SAHA), and are superior to their combined administration groups (CYT387+SAHA).

[0030] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0031] The compound with anti-psoriatic activity provided by the present invention provides a new strategy for in-depth research and development of anti-psoriatic drugs of new structural types.

[0032] The compounds with anti-psoriatic activity provided by the present invention have good pharmacodynamics in various anti-psoriatic related tests in vitro and in vivo imiquimod-induced mouse models. Compounds Z17h and Z17j exhibit better anti-psoriatic activity than their parent drugs and the combined administration of the parent drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1This is a schematic diagram of the results of Western Blot testing the effects of compounds Z17j and Z17h on acetylated H3 and H4.

[0034] Figure 2 This is a schematic diagram of the results of Western Blot testing the effects of compounds Z17j and Z17h on phosphorylated STAT5.

[0035] Figure 3 This is a schematic diagram of the results of the anti-psoriatic activity study of topical application (cream) of compounds Z17j and Z17h on the back skin of mice.

[0036] Figure 4 This is a schematic diagram of the results of a study on the anti-psoriasis activity of topical medications (creams) of compounds Z17j and Z17h.

[0037] Figure 5 This is a schematic diagram of the results of the mouse spleen study on the anti-psoriasis activity of topical application (cream) of compounds Z17j and Z17h. DETAILED DESCRIPTION

[0038] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0039] In the present invention, TCFH is tetramethyl chlorouronium hexafluorophosphate, NMI is N-methylimidazole, DCM is dichloromethane, MeOH is methanol, and THF is tetrahydrofuran.

[0040] Example 1

[0041] Synthesis of N-hydroxy-2-(4-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide (C4)

[0042]

[0043] Reagents and conditions: (a) Pd(PPh3)4, Na2CO3, 1,4-Dioxane / H2O, 100℃, 2.5h; (b) Ca, TsOH.H2O, 1,4-Dioxane, 100℃, overnight; (c) NH2OK, anhydrousCH3OH, rt, 4h.

[0044] Step a: Synthesis of N-(4-(2-chloropyrimidin-4-yl)phenyl)methanesulfonamide (C3)

[0045] 2,4-Dichloropyrimidine (C1, 0.50 g, 3.4 mmol) and 4-(methylsulfonylamino)phenylboronic acid (C2, 0.68 g, 3.1 mmol), Na2CO3 (0.66 g, 6.2 mmol), tetrakis(triphenylphosphine)palladium (0) (0.36 g, 0.31 mmol) were placed in a 100 mL two-necked flask, 18 mL of 1,4-dioxane was added, and the reaction was carried out under N2 protection for 5 min, and then 6 mL of water was added, the volume ratio of 1,4-dioxane to water was 3:1, and the reaction was refluxed at 100 ° C for 2.5 h. After the reaction was completed, the solvent was evaporated under reduced pressure, 60 mL of water was added, and 30 mL of ethyl acetate was extracted until there was no target compound in the aqueous phase, the organic layers were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography, and the mobile phase was a petroleum ether / ethyl acetate mixed solvent to obtain compound C3, 0.5 g of white solid, with a yield of 56%. 1 HNMR (600MHz, DMSO-d6) δ10.29(s,1H),8.77(d,J=5.3Hz,1H),8.21-8.16(m,2H),8.07(d,J=5.3Hz,1H),7.38-7.34(m,2H),3.11(s,3H).

[0046] Step b: Compound C3 (0.05 g, 0.18 mmol), methyl 2-(4-(4-aminophenyl)-1H-1,2,3-triazol-1-yl)acetate (Ca, 0.043 g, 0.185 mmol), p-toluenesulfonic acid monohydrate (0.027 g, 0.144 mmol) were placed in a 25 mL eggplant flask, and 5 mL of 1,4-dioxane was added, refluxed at 100 ° C for 12 h, cooled to room temperature after the reaction, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography, and the mobile phase was a petroleum ether / ethyl acetate mixed solvent (1:1) to obtain compound C4-1, 0.029 g of yellow solid, with a yield of 34%. 1 HNMR (600MHz, DMSO-d6) δ10.17(s,1H),9.81(s,1H),8.55(d,J=5.2Hz,1H),8.46(s,1H),8.18(d,J=8.6Hz,2H),7.93(d,J=8 .6Hz,2H),7.82(d,J=8.6Hz,2H),7.40(d,J=5.3Hz,1H),7.37(dd,J=8.9,2.4Hz,2H),5.46(s,2H),3.74(s,3H),3.10(s,3H). 13CNMR(151MHz,DMSO-d6)δ164.92,162.79,153.67,142.64,142.51,133.29,132.58,125.05,95.15,49.06,40.39.HRMS(ESIpositive):calclatedforC 22 H 21 N7O4S[M+H] + :480.1448,found[M+H] + :480.1453.

[0047] Step c: Dissolve hydroxylamine hydrochloride (2.34 g, 3.35 mmol) in 12 mL of methanol, and slowly drop a solution of potassium hydroxide (2.81 g, 5 mmol) in 6 mL of methanol under ice bath conditions. After the addition is complete, stir the mixture at room temperature (>30 min). After the reaction is complete, filter the precipitate, and the filtrate is the free hydroxylamine methanol solution. Dissolve compound C4-1 (0.05 g, 0.104 mmol) in the above-prepared 10 mL of hydroxylamine methanol solution, and stir the reaction at room temperature for 3.5 h. After the reaction is complete, concentrate under reduced pressure to a small amount of solvent (less than 0.5 mL), add an appropriate amount of aqueous solution, and then slowly drop acetic acid, adjust the pH to neutral, and precipitate a large amount of solid. Filter and dry to obtain the target compound C4, 0.030 g of yellow solid, with a yield of 60%. 1 H NMR (600MHz, DMSO-d6) δ9.73(s,1H),8.51(d,J=5.2Hz,1H),8.43(s,1H),8.13(d,J=8.4Hz,2H),7.93(d,J= 8.5Hz,2H),7.82(d,J=8.4Hz,2H),7.35(d,J=5.3Hz,1H),7.30(d,J=8.3Hz,2H),5.01(s,2H),3.02(s,3H). 13 CNMR(151MHz,DMSO-d6)δ163.69,160.51,159.15,146.90,140.91,130.52,128.55,126.00,124.19,122.23,119.46,119.33,107.82,50.43.HRMS(ESI positive):calculatedforC 21 H 17 N8O4S[MH]-:464.1146,found[MH]-:464.1143.

[0048] Example 2

[0049] Synthesis of N-hydroxy-3-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide (C7a)

[0050]

[0051] Reagentsandconditions:(c)NH2OK,anhydrousCH3OH,rt,4h.(d)LiOH,THF / MeOH / H2O(3:2:1),rt,3h; (e)variousamino-esters,TCFH,NMI,MeCN,DMF,rt,3h;

[0052] Step d: Compound C4-1 (0.025 g, 0.052 mmol) was dissolved in 3 mL of a mixed solvent of tetrahydrofuran / methanol / water (volume ratio of 3:2:1), and LiOH (0.005 g, 0.209 mmol) was added, and the reaction was carried out at room temperature for 3 h. After the reaction was completed, the mixture was concentrated under reduced pressure until the solvent was evaporated, and an appropriate amount of water was added. The pH was adjusted with 1.2 M hydrochloric acid. As the pH value of the system decreased, a large amount of solid precipitated. Filter and dry to obtain compound C5, 0.021 g of a yellow solid, with a yield of 87.5%. 1 HNMR(600MHz,DMSO-d6)δ13.42(s,1H),10.16(s,1H),9.78(s,1H),8.54(d,J=5.2Hz,1H),8.44(s,1H), 8.20-8.16(m,2H),7.96-7.92(m,2H),7.83-7.80(m,2H),7.40-7.35(m,3H),5.31(s,2H),3.10(s,3H). 13 CNMR(151MHz,DMSO-d6)δ169.08,163.48,160.51,159.36,146.99,141.52,140.86,131.93,128.65, 126.00,124.19,122.25,119.49,119.19,108.03,51.10,40.55.HRMS(ESIpositive):calclatedforC 21 H 19 N8O4S[M+H] + :481.1401,found[M+H] + :481.1391.

[0053] Step e: Compound C5 (0.03 g, 0.064 mmol), methyl 3-aminopropionate (0.018 g, 0.128 mmol), tetramethyl chlorouronium hexafluorophosphate (TCFH) (0.044 g, 0.156 mmol), N-hydroxysuccinimide NMI (18 μL, 0.228 mmol) were dissolved in 3 mL of acetonitrile, and then 2 mL of DMF was added, and the reaction was carried out at room temperature for 3 h. After the reaction was completed, 50 mL of water was added, and ethyl acetate (30 mL×3) was extracted, the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography, and the mobile phase was a mixed solvent of dichloromethane / methanol to obtain compound C6, 0.027 g of white solid, and the yield was 77%. 1 HNMR (600MHz, DMSO-d6) δ10.27(s,1H),9.78(s,1H),8.67(s,1H),8.54(d,J=5.2Hz,1H),8.42(d,J=1.0Hz,1H),8.17(d,J=8.4Hz,2H),7.93(d,J=8 .4Hz,2H),7.81(d,J=8.4Hz,2H),7.41-7.35(m,3H),5.12(s,2H),3.61(d ,J=1.1Hz,3H),3.36(d,J=6.3Hz,2H),3.09(s,3H),2.53(t,J=6.6Hz,2H).

[0054] Step f: The synthesis method of compound C7a refers to step c of Example 1, except that compound C4-1 is replaced by compound C6 to obtain a light yellow solid with a yield of 62.5%. 1 HNMR(600MHz,DMSO-d6)δ10.47(s,1H),9.74(s,1H),8.82(s,1H),8.52(d,J=5.2Hz,1H),8.49-8.42(m,1H),8.39(s,1H),8.17-8.12(m ,2H),7.95-7.90(m,2H),7.84-7.79(m,2H),7.37-7.29(m,3H),5.10(s,2H),3.33(d,J=6.3Hz,2H),3.05(s,3H),2.19(t,J=7.0Hz,2H). 13CNMR(151MHz,DMSO-d6)δ167.54,165.91,163.55,160.50,159.27,146.83,142.46,140.82,131.32,128.61,125 .97,124.26,122.37,119.46,119.24,107.93,52.20,40.51,35.93,32.64.HRMS(ESIpositive):calclatedforC 24 H 25 N9O5S[M+H] + :552.1772,found[M+H] + :552.1788.

[0055] Example 3

[0056] Synthesis of N-hydroxy-4-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide (C7b)

[0057]

[0058] Synthesis of methyl 4-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamido)butanoate (3-1)

[0059]

[0060] The synthesis method was as follows: step e of Example 2, except that 3-aminopropionic acid methyl ester was replaced with 4-aminobutyric acid methyl ester to obtain compound 3-1 as a white solid with a yield of 82.3%. 1 HNMR (600MHz, DMSO-d6) δ10.28(s,1H),9.77(s,1H),8.62(s,1H),8.54(d,J=5.2Hz,1H),8.43(s,1H),8.17(d,J=8.7Hz,2H),7.94-7.91(m,2H),7. 81(d,J=8.6Hz,2H),7.40-7.37(m,3H),5.13(s,2H),3.59(s,3H),3.14(q ,J=6.6Hz,2H),3.09(s,3H),2.36(t,J=7.5Hz,2H),1.70(p,J=7.1Hz,2H).

[0061] Compound C7b was synthesized using compound 3-1 as raw material. The synthesis method was similar to step c of Example 1 to obtain a light yellow solid with a yield of 66.7%.1 HNMR(600MHz,DMSO-d6)δ10.38(s,1H),9.75(s,1H),8.52(d,J=5.1Hz,1H),8.39(d,J=16.1Hz,2H),8.15(d,J=8.5Hz,2H),7.93(d,J=8.4Hz,2H),7 .81(d,J=8.3Hz,2H),7.35(dd,J=19.5,6.8Hz,3H),5.11(s,2H),3.12(q, J=6.7Hz,2H),3.06(s,3H),2.00(t,J=7.5Hz,2H),1.68(p,J=7.3Hz,2H). 13 CNMR(151MHz,DMSO-d6)δ169.19,165.81,163.55,160.50,159.29,146.83,142.38,140.82,131.38,128.61,125.97 ,124.27,122.40,119.47,119.24,107.94,52.25,40.49,38.97,30.25,25.58.HRMS(ESIpositive):calclatedforC 25 H 27 N9O5S[M+H] + :566.1929,found[M+H] + :566.1947.

[0062] Example 4

[0063] Synthesis of N-hydroxy-5-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide (C7c)

[0064]

[0065] Synthesis of ethyl 5-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamido)pentanoate (4-1)

[0066]

[0067] The synthesis method is as follows: Referring to step e of Example 2, 3-aminopropionic acid methyl ester is replaced with 5-aminovaleric acid ethyl ester to obtain compound 4-1 as a white solid with a yield of 20%. 1HNMR(600MHz,DMSO-d6)δ10.16(s,1H),9.77(s,1H),8.54(d,J=5.2Hz,1H),8.40( s,1H),8.35(t,J=5.7Hz,1H),8.18(d,J=8.5Hz,2H),7.93(d,J=8.5Hz,2H),7.82(d ,J=8.4Hz,2H),7.40-7.34(m,3H),5.11(s,2H),4.05(qd,J=7.1,0.9Hz,2H),2.31 (t,J=7.3Hz,2H),1.55(p,J=7.3Hz,2H),1.49-1.42(m,2H),1.18(t,J=7.1Hz,3H).

[0068] Compound C7c was synthesized using compound 4-1 as raw material. The synthesis method was similar to that in step c of Example 1 to obtain a light yellow solid with a yield of 62.4%. 1 HNMR(600MHz,DMSO-d6)δ10.36(s,1H),9.73(s,1H),8.51(d,J=5.2Hz,1H),8.41(s, 1H),8.36(t,J=5.5Hz,1H),8.13(d,J=8.9Hz,2H),7.93(d,J=8.9Hz,2H),7.82(d,J=8 .8Hz,2H),7.35(d,J=5.3Hz,1H),7.30(d,J=8.9Hz,2H),5.11(s,2H),3.11(q,J=6.9H z,2H),3.04(s,3H),1.97(t,J=7.3Hz,2H),1.52(p,J=7.3Hz,2H),1.48-1.38(m,2H). 13 C NMR(151MHz,DMSO-d6)δ169.36,165.70,163.61,160.50,159.22,146.82,143.07,140.84,130.95,128.58,125.97,12 4.27,122.40,119.45,119.26,107.87,52.25,40.52,39.04,32.35,28.96,23.05.HRMS(ESIpositive):calclatedforC 26 H 29 N9O5S[M+H] + :580.2085,found[M+H] + :580.2080.

[0069] Example 5

[0070] Synthesis of N-hydroxy-6-(2-(4-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide)hexanamide (C7d)

[0071]

[0072] Synthesis of methyl 6-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamido)hexanoate (5-1)

[0073]

[0074] The synthesis method refers to step e of Example 2, replacing 3-aminopropionic acid methyl ester with 6-aminohexanoic acid methyl ester to obtain compound 5-1 as a white solid with a yield of 87%. 1 HNMR(600MHz,DMSO-d6)δ10.27(s,1H),9.78(s,1H),8.58-8.51(m,2H),8.42(s ,1H),8.17(d,J=8.7Hz,2H),7.93(dd,J=8.8,2.7Hz,2H),7.81(d,J=8.6Hz,2H), 7.42-7.36(m,3H),5.12(s,2H),3.58(s,3H),3.32(s,3H),3.09(s,5H),2.30(t ,J=7.4Hz,2H),1.57-1.51(m,2H),1.44(p,J=7.1Hz,2H),1.29(q,J=8.1Hz,2H).

[0075] Compound C7d was synthesized using compound 5-1 as raw material. The synthesis method was similar to step c of Example 1 to obtain a light yellow solid with a yield of 58.8%. 1HNMR(600MHz,DMSO-d6)δ10.34(s,1H),9.75(s,1H),8.53(d,J=5.2Hz,1H),8.40(s,1H) ,8.36-8.31(m,1H),8.16(d,J=8.4Hz,2H),7.93(d,J=8.5Hz,2H),7.82(d,J=8.4Hz,2H), 7.36(dd,J=16.4,6.8Hz,3H),5.10(s,2H),3.11(q,J=6.4Hz,2H),3.07(s,3H),1.95(t,J =7.4Hz, 1H), 1.50 (p, J = 7.4Hz, 2H), 1.44 (p, J = 7.1Hz, 2H), 1.27 (dd, J = 14.4, 7.2Hz, 2H). 13 CNMR(151MHz,DMSO-d6)δ169.47,165.66,163.56,160.51,159.27,146.81,142.36,140.81,131.40,128.61,125.97,124.3 0,122.39,119.47,119.23,107.93,52.25,40.55,39.21,32.64,29.11,26.45,25.29.HRMS(ESIpositive):calclatedforC 27 H 31 N9O5S[M+H] + :594.2242,found[M+H] + :594.2252.

[0076] Example 6

[0077] Synthesis of N-hydroxy-7-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamido)heptylamide (C7e)

[0078]

[0079] Synthesis of methyl 7-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetylamino)heptanoate (6-1)

[0080]

[0081] The synthesis method is as follows: Referring to step e of Example 2, 3-aminopropionic acid methyl ester is replaced with 7-aminoheptanoic acid methyl ester to obtain compound 6-1 as a white solid with a yield of 32.7%.1 HNMR(600MHz,DMSO-d6)δ10.15(s,1H),9.77(s,1H),8.54(d,J=5.2Hz,1H),8.40 (s,1H),8.32(t,J=5.6Hz,1H),8.20-8.14(m,2H),7.93(d,J=8.8Hz,2H),7.83-7. 77(m,2H),7.40-7.32(m,3H),5.10(s,2H),3.58(d,J=1.5Hz,3H),3.10(s,5H),2. 30(t,J=7.4Hz,2H),1.52(t,J=7.2Hz,2H),1.48-1.39(m,2H),1.32-1.25(m,4H).

[0082] Compound C7e was synthesized using compound 6-1 as raw material. The synthesis method was similar to that in step c of Example 1 to obtain a light yellow solid with a yield of 73.5%. 1 HNMR(600MHz,DMSO-d6)δ10.34(s,1H),9.72(s,1H),8.50(d,J=5.2Hz,1H),8.41(s,1H) ,8.33(t,J=5.7Hz,1H),8.14-8.08(m,2H),7.95-7.91(m,2H),7.84-7.77(m,2H),7.34( d,J=5.3Hz,1H),7.27(d,J=8.6Hz,2H),5.11(s,2H),3.11(q,J=6.6Hz,2H),3.00(s,3H) ,1.94(t,J=7.4Hz,2H),1.49(p,J=7.4Hz,2H),1.43(p,J=7.0Hz,2H),1.30-1.22(m,4H). 13 CNMR(151MHz,DMSO-d6)δ169.55,165.67,163.67,160.49,159.16,146.81,143.68,140.85,130.55,128.55,125.96,124.25,1 22.40,119.43,119.29,107.81,52.25,40.53,39.26,32.68,29.24,28.73,26.54,25.51.HRMS(ESIpositive):calclatedforC 28 H 33 N9O5S[M+H] + :608.2398,found[M+H] + :608.2393.

[0083] Example 7

[0084] Synthesis of N-hydroxy-8-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide (C7g)

[0085]

[0086] Synthesis of 8-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamido)octanoic acid methyl ester (7-1)

[0087]

[0088] The synthesis method refers to step e of Example 2, except that 3-aminopropionic acid methyl ester was replaced with 8-aminocaprylic acid methyl ester to obtain a white solid with a yield of 32.7%. 1 HNMR(600MHz,DMSO-d6)δ10.16(s,1H),9.76(s,1H),8.54(d,J=5.2Hz,1H),8.40 (s,1H),8.32(t,J=5.6Hz,1H),8.20-8.15(m,2H),7.95-7.90(m,2H),7.83-7.79( m,2H),7.39-7.34(m,3H),5.10(s,2H),3.57(s,3H),3.13-3.07(m,5H),2.29(t,J =7.4Hz, 2H), 1.52 (q, J = 7.2Hz, 2H), 1.43 (t, J = 6.9Hz, 2H), 1.27 (d, J = 4.2Hz, 6H).

[0089] Compound C7g was synthesized using compound 7-1 as raw material. The synthesis method was similar to step c of Example 1 to obtain a light yellow solid with a yield of 72.7%. 1HNMR(600MHz,DMSO-d6)δ10.33(s,1H),9.74(s,1H),8.52(d,J=5.2Hz,1H),8.41(s,1H),8 .33(t,J=5.5Hz,1H),8.15(d,J=8.6Hz,2H),7.93(d,J=8.7Hz,2H),7.82(d,J=8.5Hz,2H),7 .36(d,J=5.2Hz,1H),7.32(d,J=8.4Hz,2H),5.11(s,2H),3.11(q,J=6.6Hz,2H),3.06(s,3 H),1.94(t,J=7.4Hz,2H),1.48(p,J=7.5Hz,2H),1.43(q,J=7.0Hz,2H),1.32-1.16(m,6H). 13 CNMR(151MHz,DMSO-d6)δ169.58,165.66,163.57,160.50,159.25,146.81,142.61,140.82,131.23,128.60,125.96,124.28,122 .41,119.46,119.24,107.91,52.26,40.53,39.28,32.71,29.33,28.97,28.87,26.72,25.53.HRMS(ESIpositive):calculatedfor C 29 H 35 N9O5S[M+H] + :622.2555,found[M+H] + :622.2564.

[0090] Example 8

[0091] Synthesis of N-hydroxy-2-(4-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)acetamide (C7h)

[0092]

[0093] Reagents and conditions: (e) variousamino-esters,TCFH,NMI,MeCN,DMF,rt,3h; (f)1)TFA,CH2Cl2,rt,1h; 2)NH2OCPh3,TCFH,NMI,MeCN,rt,3h; (g)BF3.Et2O,CH2Cl2,rt,1h.

[0094] The first step is the synthesis of intermediate 8-1. The synthesis method is the same as that of step e in Example 2, except that 3-aminopropionic acid methyl ester is replaced by 4-aminophenylacetic acid tert-butyl ester. The product is a white solid with a yield of 62.3%. 1 HNMR(600MHz,DMSO-d6)δ10.49(s,1H),10.15(s,1H),9.77(s,1H),8.54(d,J=5.2Hz,1H),8.49(s,1H),8.20-8.16(m,2H),7.96-7.92(m ,2H),7.85-7.81(m,2H),7.56-7.52(m,2H),7.40-7.34(m,3H),7.24-7.17(m,2H),5.37(s,2H),3.50(s,2H),3.10(s,3H),1.39(s,9H).

[0095] In the second step, the intermediate 8-1 (0.10 g, 0.15 mmol) was dissolved in 2 mL of dry dichloromethane, 1 mL of trifluoroacetic acid was added under ice bath conditions, and the reaction was carried out at room temperature for 1 h. This step of reaction is to remove the tert-butyl group, expose the carboxyl group, and then carry out a condensation reaction. Referring to step e of Example 2, 3-aminopropionic acid methyl ester was replaced with O-tritylhydroxylamine to obtain intermediate 8-2, a yellow solid, and the two-step reaction yield was 29.6%. 1 HNMR(600MHz,DMSO-d6)δ10.46(s,1H),10.43(s,1H),10.15(s,1H),9.77(s,1H),8.54(d,J=5.2Hz,1H),8.48(s,1H),8.21-8.15(m,2H),7.96 -7.91(m,2H),7.83(d,J=8.6Hz,2H),7.41(d,J=8.3Hz,2H),7.40-7.26(m,18H),6.89(d,J=8.1Hz,2H),5.35(s,2H),3.11(s,2H),3.10(s,3H).

[0096] In the third step, the intermediate 8-2 (0.03 g, 0.035 mmol) was dissolved in 2 mL of dichloromethane, and a solution of boron trifluoride in ether (9 μL, 0.07 mmol) was added under ice bath conditions. The mixture was reacted at room temperature for 1 h. A solid precipitated, which was filtered, washed three times with water, and dried to obtain 18 mg of a yellow solid, compound C7h, with a yield of 83.9%. 1HNMR (600MHz, DMSO-d6) δ10.48(s,1H),10.25(s,1H),10.02(s,1H),8.53(d,J=5.5Hz,1H),8.52(s,1H),8.22-8.17(m,2H),7.88( s,4H),7.54-7.50(m,2H),7.46(d,J=5.5Hz,1H),7.39-7.35(m,2H),7.22(d,J=8.6Hz,2H),5.37(s,2H),3.24(s,2H),3.11(s,3H). 13 CNMR(151MHz,DMSO-d6)δ167.55,164.93,164.56,158.81,157.02,146.73,142.14,131.96,131.23,129.86,129.13, 126.14,125.24,122.81,120.49,119.71,119.07,107.90,52.83,40.49,39.24.HRMS(ESIpositive):calclatedforC 29 H 27 N9O5S[M+H] + :614.1929,found[M+H] + :614.1929.

[0097] Example 9

[0098] Synthesis of N-hydroxy-2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z3)

[0099]

[0100] Reagents and conditions: (a) TsOH.H2O, 1,4-Dioxane, 110℃, overnight; (b) NaOH, NH2OH (50% inwater), THF / MeOH (1:1), rt, 4h.

[0101] Synthesis of intermediate Z2: The synthesis method is as follows: step b of Example 1, except that 2-(4-(4-aminophenyl)-1H-1,2,3-triazol-1-yl)acetic acid methyl ester is replaced by compound Z1 (2-(4-(4-aminophenyl)piperazin-1-yl)acetic acid methyl ester) to obtain intermediate Z2 as a yellow solid in a yield of 26.6%. 1HNMR (600MHz, DMSO-d6) δ10.14(s,1H),9.36(s,1H),8.44(d,J=5.2Hz,1H),8.14-8.10(m,2H),7.65(d,J=8.8Hz,2H),7.34(d,J =8.5Hz,2H),7.26(d,J=5.1Hz,1H),6.95-6.89(m,2H),3.63(s,3H),3.29(s,2H),3.08(d,J=5.3Hz,7H),2.65(t,J=5.0Hz,4H). 13 CNMR(151MHz,DMSO-d6)δ170.89,163.28,160.75,159.26,146.56,141.35,133.27,132.1 6,128.52,120.68,119.17,116.49,107.08,58.80,52.55,51.66,49.49,40.51.HRMS(ESI positive):calculatedforC 24 H 28 N6O4S[M+H] + :497.1966,found[M+H] + :497.1960.

[0102] Synthesis of compound Z3: NaOH (0.032 g, 0.8 mmol) was dissolved in 50% hydroxylamine aqueous solution (1 mL) to prepare fresh NaOH-hydroxylamine aqueous solution, intermediate Z2 (0.05 g, 0.10 mmol) was dissolved in 2 mL tetrahydrofuran / methanol (volume ratio of 1:1) mixed solvent, NaOH-hydroxylamine aqueous solution was added dropwise under ice bath, the temperature was slowly raised to room temperature, and the reaction was carried out for 3 h. The mixture was concentrated under reduced pressure, excess saturated saline was added, and the pH was adjusted to neutral with acetic acid, a large amount of solid was precipitated, and it was filtered and dried to obtain a light yellow solid, namely compound Z3, with a yield of 72.4%. 1 HNMR (600MHz, DMSO-d6) δ10.43(s,1H),9.32(s,1H),8.80(s,1H),8.42(d,J=5.2Hz,1H),8.11-8.07(m,2H),7.68-7.62(m,2H),7.28( d,J=8.7Hz,2H),7.24(d,J=5.3Hz,1H),6.92(d,J=9.1Hz,2H),3.09(t,J=5.1Hz,4H),3.03(s,3H),2.93(s,2H),2.58(t,J=5.0Hz,4H). 13CNMR(151MHz,DMSO-d6)δ166.14,163.43,160.75,159.13,146.54,142.89,133.26,131.19,128.46 ,120.67,119.24,116.39,106.94,59.61,53.30,49.36,40.54.HRMS(ESIpositive):calclatedforC 23 H 27 N7O4S[M+H] + :498.1918,found[M+H] + :498.1926.

[0103] Example 10

[0104] Synthesis of N-(2-aminophenyl)-2-(4-(4-((4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z5)

[0105]

[0106] Reagents and conditions: (c) LiOH, THF / MeOH / H2O (3:2:1), rt, 3h; (d) O-Phenylendiamine, HATU, DIPEA, DMF, rt, 8h; (f) various amino-esters, TCFH, MeCN, DMF, rt, 3h.

[0107] The synthesis method was similar to that of step d in Example 2 to obtain compound Z4 as a yellow solid in a yield of 70.5%. 1 HNMR(600MHz,DMSO-d6)δ10.20(s,1H),9.42(s,1H),8.45(d,J=5.2Hz,1H),8.15-8.10(m,2H),7.73-7.66(m,2H),7.37-7.32 (m,2H),7.28(d,J=5.2Hz,1H),6.97(d,J=8.9Hz,2H),3.82(s,2H),3.31(t,J=5.0Hz,4H),3.20(t,J=5.0Hz,4H),3.09(s,3H). 13CNMR(151MHz,DMSO-d6)δ163.32,161.30,160.68,159.27,141.41,132.09,128.52,120.60,119 .19,117.44,117.19,107.28,46.79,45.18,43.19,40.50.HRMS(ESIpositive):calclatedforC 23 H 26 N6O4S[M+H] + :483.1809,found[M+H] + :483.1810.

[0108] The synthesis method was similar to that of step e in Example 2 to obtain a pale yellow solid, namely compound Z5, with a yield of 42.1%. 1 HNMR (600MHz, DMSO-d6) δ10.13(s,1H),9.35(s,1H),9.19(s,1H),8.44(d,J=5.2Hz,1H),8. 15-8.10(m,2H),7.66(d,J=9.2Hz,2H),7.34(d,J=8.8Hz,2H),7.31(dd,J=7.9,1.6Hz,1H),7 .26(d,J=5.2Hz,1H),6.97-6.88(m,3H),6.77(dd,J=8.0,1.5Hz,1H),6.59(td,J=7.6,1.5H z,1H),4.78(s,2H),3.20(s,2H),3.16(t,J=5.1Hz,4H),3.08(s,3H),2.72(t,J=4.8Hz,4H). 13 C NMR(151MHz,DMSO-d6)δ168.58,160.76,159.27,146.56,141.98,141.37,133.27,132.16,128.53,126.16,125.08,124 .34,120.70,119.18,117.24,116.90,116.46,107.09,61.94,53.33,49.54,40.53.HRMS(ESIpositive):calclatedforC 29 H 32 N8O3S[M+H] + :573.2391,found[M+H] + :573.2388.

[0109] Embodiment 11

[0110] Synthesis of N-hydroxy-3-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17a)

[0111]

[0112] Reagentsandconditions:(d)variousamino-esters,TCFH,MeCN,DMF,rt,3h.(b)NaOH,NH2OH(50%inwater),THF / MeOH(1:1),rt,4h.

[0113] The synthesis method of intermediate 11-1 refers to step e of Example 2 to obtain intermediate 11-1 as a yellow solid with a yield of 28.4%. 1 HNMR(600MHz,DMSO-d6)δ10.14(s,1H),9.35(s,1H),8.44(d,J=5.1Hz,1H ),8.15-8.11(m,2H),7.87(s,1H),7.69-7.62(m,2H),7.38-7.31(m,2H),7 .26(d,J=5.2Hz,1H),6.95-6.90(m,2H),3.60(s,3H),3.35(q,J=6.5Hz,2H ),3.12(s,4H),3.08(s,3H),2.96(s,2H),2.57(s,4H),2.52-2.50(m,2H).

[0114] The synthesis method of compound Z17a refers to step f of Example 2 to obtain a yellow solid with a yield of 70.4%. 1 HNMR(600MHz,DMSO-d6)δ10.45(s,1H),9.36(s,1H),8.77(s,1H),8.44(d,J=5.2 Hz,1H),8.15-8.08(m,2H),7.86(t,J=5.9Hz,1H),7.68-7.62(m,2H),7.35-7.29 (m,2H),7.26(d,J=5.2Hz,1H),6.95-6.88(m,2H),3.32-3.29(m,2H),3.16-3.09 (m,4H),3.08(s,3H),2.95(s,2H),2.57(t,J=5.0Hz,4H),2.17(t,J=6.9Hz,2H). 13CNMR(151MHz,DMSO-d6)δ169.53,167.94,163.32,160.76,159.24,146.56,141.69,133.26,131.96,128.52,12 0.70,119.18,116.41,107.06,61.65,53.39,49.43,40.52,35.45,32.71.HRMS(ESIpositive):calclatedforC 26 H 32 N8O5S[M+H] + :569.2289,found[M+H] + :569.2289.

[0115] Example 12

[0116] Synthesis of N-hydroxy-4-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17b)

[0117]

[0118] Synthesis of methyl 4-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)butyrate (12-1)

[0119]

[0120] The synthesis method of compound 12-1 was similar to that of Example 11, and a yellow solid was obtained with a yield of 76.4%. 1 HNMR(600MHz,DMSO-d6)δ10.10(s,1H),9.32(s,1H),8.44(d,J=5.2Hz,1H),8 .15-8.10(m,2H),7.80(s,1H),7.68-7.62(m,2H),7.36-7.32(m,2H),7.26(d, J=5.2Hz,1H),6.95-6.91(m,2H),3.59(s,3H),3.12(q,J=6.7Hz,6H),3.08(s ,3H),2.97(s,2H),2.59(s,4H),2.31(t,J=7.5Hz,2H),1.69(p,J=7.2Hz,2H).

[0121] Synthesis of compound Z17b: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 66.7%. 1HNMR (600MHz, DMSO-d6) δ10.38 (s, 1H), 9.35 (s, 1H), 8.44 (d, J = 5.2Hz, 1H), 8.15-8. 08(m,2H),7.82(t,J=6.0Hz,1H),7.69-7.61(m,2H),7.36-7.29(m,2H),7.26(d,J=5. 2Hz,1H),6.97-6.87(m,2H),3.12(q,J=4.5Hz,4H),3.09(d,J=6.6Hz,2H),3.07(s,3 H), 2.96 (s, 2H), 2.58 (t, J = 5.0Hz, 4H), 1.95 (t, J = 7.5Hz, 2H), 1.65 (p, J = 7.3Hz, 2H). 13 CNMR(151MHz,DMSO-d6)δ169.56,169.27,163.33,160.76,159.22,146.56,141.83,133.25,131.86, 128.51,120.70,119.18,116.40,107.04,61.82,53.42,49.38,40.53,38.43,30.43,25.98.HRMS(ESI positive):calculatedforC 27 H 34 N8O5S[M+H] + :583.2446,found[M+H] + :583.2458.

[0122] Embodiment 13

[0123] Synthesis of N-hydroxy-5-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17c)

[0124]

[0125] Synthesis of Ethyl 5-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)pentanoate

[0126]

[0127] The synthesis method of compound 13-1 was referred to Example 11 to obtain a yellow solid with a yield of 31.2%. 1H NMR (600MHz, DMSO-d6) δ10.11 (s, 1H), 9.33 (s, 1H), 8.44 (d, J = 5.1 Hz, 1H), 8.13 (dd, J = 8.7, 2.7 Hz, 2H), 7.76 (s, 1H), 7.65 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 5.2 Hz, 1H), 6.93 ( d,J=8.6Hz,2H),4.05(q,J=7.1Hz,2H),3.17-3.05(m,9H),2.96(s,2H),2.59(s,4H),2.30(t,J =7.3Hz,2H),1.52(dt,J=14.7,7.6Hz,2H),1.44(dt,J=14.1,7.2Hz,2H),1.17(t,J=7.0Hz,3H).

[0128] Synthesis of compound Z17c: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 65%. 1 HNMR(600MHz,DMSO-d6)δ10.34(s,1H),10.13(s,1H),9.36(s,1H),8.67(s,1H),8.44(d,J= 5.2Hz,1H),8.15-8.08(m,2H),7.77(t,J=6.0Hz,1H),7.68-7.62(m,2H),7.35-7.29(m,2H), 7.26(d,J=5.3Hz,1H),6.97-6.89(m,2H),3.12(t,J=5.0Hz,4H),3.11-3.07(m,5H),2.96(s, 2H), 2.58 (t, J = 5.0Hz, 4H), 1.95 (t, J = 7.2Hz, 2H), 1.52-1.44 (m, 2H), 1.40 (p, J = 6.9Hz, 2H). 13 CNMR(151MHz,DMSO-d6)δ169.46,169.40,163.32,160.76,159.24,146.56,141.62,133.25,132.00,128.53,120.70,1 19.18,116.41,107.06,61.83,53.42,49.40,40.55,38.39,32.41,29.34,23.05.HRMS(ESIpositive):calclatedforC 28 H 36 N8O5S[M+H] +:597.2602,found[M+H] + :597.2613.

[0129] Embodiment 14

[0130] Synthesis of N-hydroxy-6-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17d)

[0131]

[0132] Synthesis of methyl 6-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)hexanoate (14-1)

[0133]

[0134] The synthesis method of compound 14-1 was similar to Example 11 to obtain a yellow solid with a yield of 71.5%. 1 HNMR(600MHz,DMSO-d6)δ10.14(s,1H),9.36(s,1H),8.45(d,J=5.2Hz,1H),8.15-8.1 0(m,2H),7.74(s,1H),7.67-7.63(m,2H),7.36-7.32(m,2H),7.27(d,J=5.2Hz,1H),6. 95-6.91(m,2H),3.58(s,3H),3.15-3.06(m,9H),2.96(s,2H),2.58(s,4H),2.30(t,J= 7.4Hz,2H),1.53(p,J=7.4Hz,2H),1.42(p,J=7.3Hz,2H),1.26(dq,J=5.4,2.6Hz,2H).

[0135] Synthesis of compound Z17d: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 62.4%. 1HNMR(600MHz,DMSO-d6)δ10.32(s,1H),9.34(s,1H),8.65(s,1H),8.44(d,J=5.2Hz,1H),8.14- 8.08(m,2H),7.73(t,J=6.0Hz,1H),7.67-7.62(m,2H),7.34-7.29(m,2H),7.26(d,J=5.2Hz,1H) ,6.95-6.91(m,2H),3.15-3.10(m,4H),3.08(d,J=11.3Hz,5H),2.95(s,2H),2.57(t,J=5.0Hz, 4H), 1.93 (t, J = 7.4Hz, 2H), 1.49 (p, J = 7.5Hz, 2H), 1.41 (p, J = 7.3Hz, 2H), 1.23 (q, J = 8.3Hz, 2H). 13 CNMR(151MHz,DMSO-d6)δ169.51,169.37,163.32,160.75,159.21,146.55,141.77,133.23,131.89,128.50,120.70,119. 18,116.40,107.04,61.83,53.40,49.37,40.52,38.59,32.67,29.43,26.47,25.32.HRMS(ESIpositive):calclatedforC 29 H 38 N8O5S[M+H] + :611.2759,found[M+H] + :611.2752.

[0136] Embodiment 15

[0137] Synthesis of N-hydroxy-7-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17e)

[0138]

[0139] Synthesis of methyl 7-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetylamino)heptanoate (15-1)

[0140]

[0141] The synthesis method of compound 15-1 was similar to Example 11 to obtain a yellow solid with a yield of 46.6%. 1HNMR(600MHz,DMSO-d6)δ10.15(s,1H),9.36(s,1H),8.44(d,J=5.2Hz,1H),8.15-8.08(m ,2H),7.75(s,1H),7.65(d,J=8.8Hz,2H),7.36-7.32(m,2H),7.27(d,J=5.2Hz,1H),6.93 (d,J=9.0Hz,2H),3.57(s,3H),3.10(d,J=23.9Hz,9H),2.97(s,2H),2.59(s,4H),2.29(t ,J=7.4Hz,2H),1.51(p,J=7.3Hz,2H),1.41(p,J=7.2Hz,2H),1.25(dd,J=5.9,2.7Hz,4H).

[0142] Synthesis of compound Z17e: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 48.5%. 1 HNMR(600MHz,DMSO-d6)δ10.32(s,1H),9.35(s,1H),8.65(s,1H),8.44(d,J=5.2Hz,1H),8.1 4-8.09(m,2H),7.74(t,J=6.0Hz,1H),7.68-7.62(m,2H),7.36-7.30(m,2H),7.26(d,J=5.3H z,1H),6.96-6.89(m,2H),3.12(t,J=5.0Hz,4H),3.08(s,5H),2.96(s,2H),2.58(t,J=5.0Hz ,4H),1.93(t,J=7.4Hz,2H),1.50-1.44(m,2H),1.40(d,J=6.7Hz,2H),1.24(p,J=3.8Hz,4H). 13 CNMR(151MHz,DMSO-d6)δ169.56,169.36,163.33,160.75,159.21,146.53,141.86,133.24,131.82,128.50,120.69,119. 18,116.39,107.03,61.82,53.39,49.37,38.64,32.69,29.57,28.75,26.58,25.55.HRMS(ESIpositive):calclatedforC 30 H 40 N8O5S[M+H] + :625.2915,found[M+H] + :625.2916.

[0143] Example 16

[0144] Synthesis of N-hydroxy-8-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17g)

[0145]

[0146] Synthesis of 8-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)octanoic acid methyl ester (16-1)

[0147]

[0148] The synthesis method of compound 16-1 was similar to Example 11 to obtain a yellow solid with a yield of 37%. 1 HNMR(600MHz,DMSO-d6)δ10.15(s,1H),9.36(s,1H),8.44(d,J=5.2Hz,1H),8.13(d,J=8.9Hz,2H), 7.76-7.71(m,1H),7.65(d,J=9.2Hz,2H),7.34(d,J=8.9Hz,2H),7.27(d,J=5.2Hz,1H),6.93(d,J= 9.3Hz,2H),3.57(s,3H),3.12(t,J=5.0Hz,4H),3.08(d,J=3.2Hz,5H),2.96(s,2H),2.58(t,J=4.8 Hz,4H),2.30-2.27(m,2H),1.53-1.50(m,2H),1.41(dt,J=14.2,7.1Hz,2H),1.26(d,J=5.0Hz,6H).

[0149] Synthesis of compound Z17g: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 72.1%. 1HNMR(600MHz,DMSO-d6)δ10.32(s,1H),9.31(s,1H),8.41(d,J=5.2Hz,1H),8.08(d,J=8.9H z,2H),7.73(t,J=5.9Hz,1H),7.66(d,J=9.2Hz,2H),7.27(d,J=8.9Hz,2H),7.23(d,J=5.3Hz ,1H),6.93(d,J=9.3Hz,2H),3.15-3.05(m,6H),3.02(s,3H),2.95(s,2H),2.58(t,J=5.1Hz, 4H),1.93(t,J=7.4Hz,2H),1.48(p,J=7.6Hz,2H),1.41(t,J=7.4Hz,2H),1.27-1.20(m,6H). 13 C NMR(151MHz,DMSO-d6)δ169.67,169.49,163.37,160.72,159.16,146.52,142.44,133.21,131.44,128.46,120.72,119.26,116 .39,106.98,61.76,53.35,49.35,40.40,38.65,32.67,29.59,28.94,28.83,26.70,25.49.HRMS(ESIpositive):calclatedforC 31 H 42 N8O5S[M+H] + :639.3072,found[M+H] + :625.3062.

[0150] Embodiment 17

[0151] Synthesis of (E)-N-hydroxy-3-(4-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)phenyl)acrylamide (Z17h)

[0152]

[0153] Synthesis of ethyl (E)-3-(4-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)phenyl)acrylate (17-1)

[0154]

[0155] The synthesis method of compound 17-1 is shown in Example 11, yellow solid, 0.04 g, yield 55.5%.1 H NMR (600MHz, DMSO-d6) δ10.14(s,1H),9.99(s,1H),9.37(s,1H),8.45(d,J=5.2Hz, 1H),8.13(d,J=8.9Hz,2H),7.75-7.64(m,6H),7.59(d,J=16.0Hz,1H),7.34(d,J=8 .8Hz,2H),7.27(d,J=5.3Hz,1H),6.95(d,J=9.4Hz,2H),6.53(d,J=16.0Hz,1H),4. 18(q,J=7.1Hz,2H),3.23(s,2H),3.09(s,3H),2.69(s,4H),1.25(t,J=7.1Hz,3H).

[0156] Synthesis of compound Z17h: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 43.8%. 1 HNMR(600MHz,DMSO-d6)δ10.68(s,1H),9.93(s,1H),9.36(s,1H),9.01(s,1H),8.44(d, J=5.2Hz,1H),8.11(s,2H),7.69(dd,J=26.9,9.0Hz,4H),7.52(d,J=8.8Hz,2H),7.40(d, J=16.0Hz,1H),7.31(d,J=8.8Hz,2H),7.26(d,J=5.3Hz,1H),6.94(d,J=9.3Hz,2H),6.3 7(d,J=15.8Hz,1H),3.21(s,2H),3.18-3.14(m,4H),3.06(s,3H),2.68(t,J=5.1Hz,4H). 13 CNMR(151MHz,DMSO-d6)δ168.92,163.36,160.77,159.20,146.55,142.88,142.02,140.19,138.35,133.31,131.76,130.39,128 .59,128.50,120.69,120.01,119.21,117.99,116.48,107.04,62.26,53.28,49.44,40.56.HRMS(ESIpositive):calclatedforC 32 H 34 N8O5S[M+H] + :643.2446,found[M+H] + :643.2450.

[0157] Embodiment 18

[0158] Synthesis of N-hydroxy-5-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetylamino)thiophene-2-carboxamide (Z17i)

[0159]

[0160] Synthesis of 5-(2-(4-(4-(methylsulfonylamino)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)thiophene-2-carboxylic acid methyl ester (18-1)

[0161]

[0162] The synthesis method of compound 18-1 was similar to Example 11, and a yellow solid was obtained with a yield of 72.7%. 1 HNMR(600MHz,DMSO-d6)δ11.51(s,1H),10.13(s,1H),9.35(s,1H),8.44(d,J =5.2Hz,1H),8.16-8.10(m,2H),7.69-7.64(m,2H),7.61(d,J=4.2Hz,1H),7. 37-7.31(m,2H),7.26(d,J=5.3Hz,1H),6.97-6.91(m,2H),6.89(d,J=4.2Hz, 1H), 3.78 (s, 3H), 3.16 (q, J = 5.1Hz, 4H), 3.08 (s, 3H), 2.66 (t, J = 4.9Hz, 4H).

[0163] Synthesis of compound Z17i: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 77.8%. 1 HNMR(600MHz,DMSO-d6)δ11.24(s,1H),9.35(s,1H),8.96(s,1H),8.44(d,J=5.2Hz,1H),8.16-8.08(m,2H),7.69-7.63(m,2H),7.41(s,1H),7 .36-7.30(m,2H),7.26(d,J=5.2Hz,1H),6.97-6.89(m,2H),6.79(d,J=4.1Hz,1H),3.15(t,J=5.0Hz,4H),3.08(s,3H),2.65(t,J=5.0Hz,4H). 13CNMR(151MHz,DMSO-d6)δ167.57,163.31,160.76,159.25,146.55,141.52,133.28,132.0 7,128.53,120.71,119.18,116.46,112.28,107.08,61.34,53.30,49.28,40.53.HRMS(ESI positive):calculatedforC 28 H 30 N8O5S2[M+H] + :623.1853,found[M+H] + :623.1848.

[0164] Embodiment 19

[0165] Synthesis of N-hydroxy-4-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamide (Z17j)

[0166]

[0167] Synthesis of methyl 4-(2-(4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)benzoate (19-1)

[0168]

[0169] The synthesis method of compound 19-1 was similar to Example 11 to obtain a yellow solid with a yield of 80%. 1 HNMR(600MHz,DMSO-d6)δ10.12(d,J=8.7Hz,2H),9.35(s,1H),8.44(d,J=5.1 Hz,1H),8.15-8.11(m,2H),7.94-7.90(m,2H),7.83-7.79(m,2H),7.68-7.64 (m,2H),7.36-7.31(m,2H),7.26(d,J=5.2Hz,1H),6.96-6.92(m,2H),3.82(s ,3H),3.24(s,2H),3.16(t,J=5.1Hz,4H),3.08(s,3H),2.69(t,J=4.9Hz,4H).

[0170] Synthesis of compound Z17j: The synthesis method was similar to that of step f in Example 2 to obtain a yellow solid with a yield of 62%. 1HNMR (600MHz, DMSO-d6) δ11.05(s,1H),9.96(s,1H),9.35(s,1H),8.96(s,1H),8.44(d,J=5.1Hz,1H),8.14-8.09(m,2H),7.73(s,4H),7.68-7. 64(m,2H),7.35-7.30(m,2H),7.26(d,J=5.3Hz,1H),6.97-6.92(m,2H), 3.22(s,2H),3.16(t,J=4.9Hz,4H),3.07(s,3H),2.69(t,J=5.0Hz,4H). 13 CNMR(151MHz,DMSO-d6)δ169.11,164.31,163.32,160.76,159.24,146.56,141.71,141.60,133.29,131.95,128.52,128 .10,127.90,120.69,119.24,119.18,116.48,107.06,62.23,53.27,49.42,40.53.HRMS(ESIpositive):calclatedforC 30 H 32 N8O5S[M+H] + :617.2289,found[M+H] + :617.2293.

[0171] Embodiment 20

[0172] Test on the activity of the compounds prepared in Examples 1 to 19 of the present invention in inhibiting JAK and HDAC target sites

[0173] (1) Compound inhibition of JAK activity test

[0174] (i) First, dilute the compound to a solution with a concentration of 10000 nM, and transfer 40 μL of the compound solution to an Echo plate. Then, use ECHO650 to transfer 200 nL of the compound from the Echo plate to a 384-well plate, and mark the 384-well plate as a reaction plate.

[0175] (ii) Add JAK kinase to kinase buffer to form enzyme solution; then transfer 10 μL of the enzyme solution to the reaction wells of the 384-well plate (add kinase buffer to the negative control wells), centrifuge at 1000 rpm for 1 minute, and incubate at room temperature for 10 minutes. Then add FAM-labeled peptide and ATP to kinase buffer to form substrate solution; then transfer 10 μL of substrate solution to the reaction wells of the 384-well plate, centrifuge at 1000 rpm for 1 minute, and react at room temperature for 30 minutes; finally prepare 2 times antibody-containing stop reaction solution, add 20 μL of stop reaction solution to the 384-well reaction plate, centrifuge at 1000 rpm for 1 minute, leave at room temperature for 60 minutes, and read the fluorescence value on an ELISA reader (Envision2104MultilabelReader).

[0176] (iii) The inhibition rate was calculated based on the obtained fluorescence data. Finally, the data was imported into MS Excel and curve fitting was performed using XLFit exceladd-inversion5.4.0.8 to obtain the IC 50 .

[0177] (2) Compound inhibition test of HDAC

[0178] (i) All drugs were prepared into solutions with an initial concentration of 10 mM, a buffer solution was prepared in advance according to the ratio, and the test compound was diluted (three-fold dilution) using the buffer solution containing 10% DMSO, and the concentrations of the compounds were 100 μM, 33 μM, 10 μM, 3 μM, 1 μM, 0.3 μM, 0.1 μM, 0.03 μM, 0.01 μM, and 0.003 μM, respectively;

[0179] (ii) adding 35 μL of buffer containing 0.2 μg / mL HDAC enzyme to wells 1-11 of a black 96-well plate;

[0180] (iii) 5 μL of the compound at different concentrations was added to the reaction wells according to the dilution gradient. 5 μL and 40 μL of buffer were added to the negative control well (11th well) and the blank control well (12th well), respectively.

[0181] (iv) Add 5 μL of HDAC substrate (100 μM) and 5 μL of trypsin (0.5 mg / mL) to all reaction wells, incubate at 37°C in the dark for 30 min, and measure the fluorescence intensity of the substrate at an excitation wavelength of 360 nm and an emission wavelength of 460 nm.

[0182] (v) Calculate the inhibition rate according to the formula:

[0183] Inhibition rate (%) = (negative control well - sample well) / (negative control well - blank control well) × 100

[0184] The logarithmic conversion of the concentration was performed using GraphPad software, and then the logarithmic concentration and inhibition rate curves were fitted to obtain the IC 50 value of the compound.

[0185] Using LanceUltraAssay, the inhibition rates of the compounds (100 nM) prepared in Examples 1 to 19 of the present invention on JAK1 and JAK2 and the inhibitory activities of Z17j and Z17h on other JAK subtypes were tested under the condition of KmATP; using Fluorescent-based HDAC activity assay, with SAHA as the standard control, the inhibitory enzyme activities of the compounds prepared in Examples 1 to 19 of the present invention on HDAC1 and the inhibitory activities of Z17j and Z17h on other HDAC subtypes were tested.

[0186] The experimental results are shown in Table 1. Table 1 is the structure of the initial screening of the activities of the compounds prepared in Examples 1 to 19 of the present invention against JAK1 and JAK2 targets. It can be seen from the table that when the concentration of the compounds of the present invention is 100 nM, the inhibition rates of most compounds (except Z3, Z17a, Z17c, and Z17h) on JAK1 reach more than 90%, and the inhibition rates of all compounds on JAK2 reach more than 96%, and the inhibitory activities of these compounds on JAK2 are higher than those on JAK1. Structure-activity relationship (SAR) studies found that without changing the structure (aminopyrimidine) of the hinge region, only modifying the solvent-exposed region of the JAK inhibitor had no obvious effect on the JAK activity, indicating that the structure of the hinge region is particularly important for the inhibitory activity of JAK, and the influence of other parts can be almost ignored.

[0187] Regarding the inhibitory activity on HDAC1, except for compounds C4, C7h, Z3, Z17a, and Z5 (IC 50 > 2 μM), the remaining compounds showed good inhibitory activities on HDAC1 (IC 50 range: 22 nM to 970 nM). For the target compounds C4 - C7h (containing a triazole structural fragment), when the Linker is an alkyl chain and the chain length is 0, the inhibitory activity on HDAC1 enzyme is the weakest, and the compounds containing an aromatic Linker also have poor inhibitory activities on HDAC1 enzyme. Among the remaining compounds containing an alkyl chain, the inhibitory activity on HDAC1 is the best when the carbon chain length is 5. SAR studies showed that the HDAC1 enzyme inhibitory activities of the target compounds Z3 - Z17j (containing a piperazine structural fragment) increased with the extension of the alkyl Linker (Z3, Z17a, Z17b < Z17c, Z17d < Z17e < Z17g), that is, the compound with a Linker chain length of 7 methylene groups had the best inhibitory activity on HDAC1 enzyme (IC50 =46nM), compounds Z3 and Z17a (alkyl chain length is 2 methylene groups) with 0 alkyl chain length have inhibitory activity against HDAC1 greater than 2μM. For compounds containing aromatic linkers, compounds (Z17h, Z17i, and Z17j) have better inhibitory activity against HDAC1 enzyme (IC 50 <100nM); In addition, the structure of ZBG also has a great influence on the HDAC1 enzyme inhibitory activity. Compound Z5 (ZBG is an o-aminobenzamide group, IC 50 >100 μM) was significantly lower than that of compounds containing hydroxamic acid structure (IC 50 >2μM). When the linker is the same, the Cap structure of the HDAC inhibitor affects the inhibitory activity of the target molecule on HDAC1 enzyme, such as the target molecule C7g (IC 50 =280 nM) and Z17g (IC 50 =46nM) had a 6-fold difference in HDAC1 inhibitory activity. Compared with the Z3-Z17j series of compounds, the C4-C7h series of compounds (containing triazole structural fragments) seemed to lose their HDAC1 enzyme inhibitory activity when the linker was an aromatic group (C7h, IC 50 >2μM).

[0188] Table 1

[0189]

[0190] The results are shown in Table 2. The inhibitory activities of Z17j and Z17h on other JAK subtypes reached the nanomolar level, and they had a certain selectivity for JAK2 (as shown in Table 2, which is the test of the selectivity of Z17h and Z17j in the present invention on JAK subtypes). Z17h and Z17j had good inhibitory activities on all JAK subtypes (IC 50 The inhibitory activity of Z17h against JAK2 was 19 times that of JAK1, 11 times that of JAK3, and 6 times that of TYK2; the inhibitory activity of Z17j against JAK2 was 17 times that of JAK1, 11 times that of JAK3, and 5 times that of TYK2; therefore, both compounds Z17h and Z17j showed good selectivity for JAK2 (IC 50 values ​​were 0.72 nM and 0.49 nM, respectively).

[0191] Table 2

[0192]

[0193] The results are shown in Table 3, which is a test of the selectivity of Z17h and Z17j in the compounds of the present invention for HDAC subtypes. Some of the compounds of the present invention have good activity against HDAC1, among which Z17j and Z17h have certain advantages against HDAC1 and HDAC6, reaching the nanomolar level (IC 50 12nM and 45nM, respectively), while the inhibitory activity against other isoforms (HDAC2, HDAC3, HDAC8) was lower.

[0194] Table 3

[0195]

[0196] Embodiment 21

[0197] In vitro TNF-α-induced inhibition experiment of HaCaT cells by the compounds of the present invention

[0198] (i) Plating: 96-well plate, surrounded by a circle of PBS (100 μL per well). HaCaT cells in logarithmic growth phase were taken and prepared into a single cell suspension using DMEM complete medium. The cell density was 3.5×10 4 cells / mL, and then the suspension was evenly inoculated into a 96-well plate (wells 2-11), 100 μL per well, and cultured for 24 h under 5% CO2 and 37°C;

[0199] (ii) The supernatant was aspirated and HaCaT cells were induced with 100 ng / mL TNF-α for 24 h (wells 2-10).

[0200] Preparation of drug solution: Use cell-grade DMSO to prepare the test drugs into 10mM solution and store it at -20℃. Before the experiment, take out the drug solution, thaw it at room temperature, and dilute it by half with DMEM complete medium to obtain drug solution samples with concentrations of 100μM, 50μM, 25μM, 12.5μM, 6.25μM, 3.125μM, 1.56μM, and 0.78μM, which are prepared and used immediately.

[0201] (iii) aspirate the supernatant, set up triplicate wells, add the prepared drug solution into wells 2-9 in gradient concentrations, add DMEM complete medium without the compound into wells 10-11, and continue culturing for 48 h under 5% CO2 and 37°C;

[0202] (iv) Remove the cell supernatant and remove the PBS in the 12th well (blank well). The 10th well is the control well. Add 100 μL of 10% CCK-8 solution to each well. Incubate at 37°C for 30 min to 60 min. Measure the absorbance (OD value) at 450 nm and calculate the inhibition rate, IC, according to the following formula: 50The values ​​were calculated by GraphPad software. Inhibition rate (%) = (OD value of control well - OD value of experimental well) / OD value of control well - OD value of blank well × 100.

[0203] Table 4

[0204]

[0205]

[0206] The structural formulas of CYT387, Tofacitinib, and SAHA are shown below:

[0207]

[0208] The experimental results are shown in Table 4. Z17d, Z17e, Z5, Z17h, Z17i and Z17j have certain anti-TNF-α induced HaCaT cell proliferation activity (IC 50 <10μM), among which Z17h and Z17j are two compounds with better inhibitory activity against TNF-α-induced HaCaT cells in vitro, which is basically consistent with the results of HDAC1 inhibition in vitro. Their antiproliferative activities are 0.295μM and 1.139μM, respectively, which are better than their parent drugs and their combination (SAHAIC 50 =2.75μM, CYT387IC 50 =13.1μM, SAHA+CYT387IC 50 =1.77 μM), which is stronger than the marketed positive drug tofacitinib.

[0209] Embodiment 22

[0210] Experiment on the inhibition of NO release by macrophages by the compounds of the present invention

[0211] (i) RAW264.7 cells were subcultured in a culture dish at 5% CO2 and 37°C using DMEM complete medium (one generation every 24 hours);

[0212] (ii) RAW264.7 cells in the logarithmic growth phase were cultured at a density of 2.0×10 5 cells / mL cell suspension and seeded in 24-well plates and cultured in a 5% CO2, 37°C incubator for 24 h;

[0213] (iii) DMEM complete medium was used to prepare culture medium containing LPS (1 μg / mL), and then different drug solution samples (concentration of 0.4 μM) were prepared with it. The supernatant was removed from the 24-well plate and divided into negative control (only LPS stimulation), blank control (no additional drug and LPS) and experimental group, and different culture medium was added to each well and cultured for 24 h;

[0214] (iv) The NO content in the supernatant was detected using a NO detection kit.

[0215] (a) Preheat the microplate reader for more than 30 min, collect the supernatant, and centrifuge at 3500 rpm for 10 min;

[0216] (b) Reagent 2 was heated and shaken at 60°C for 15 min.

[0217] Blank tube = Extraction solution (100 μL) + Reagent 1 (50 μL) + Reagent 2 (50 μL)

[0218] Assay tube = sample solution (100 μL) + reagent 1 (50 μL) + reagent 2 (50 μL)

[0219] Add the samples to the 96-well plate in order, mix well, and incubate at room temperature in the dark for 15 min.

[0220] (c) Detect the OD value at 550 nm using an enzyme reader, and finally calculate the NO content according to the formula.

[0221] NO content (μmoL / L) = 250×(A 测定 -A 空白 +0.0103)

[0222] The experimental results are shown in Table 5. Z17h and Z17j showed excellent ability to inhibit LPS-induced macrophage release of NO, had certain anti-inflammatory effects, and were superior to tofacitinib, and were also stronger than its parent drug and its combination (SAHA, CYT387, SAHA+CYT387).

[0223] Table 5

[0224]

[0225]

[0226] Embodiment 23

[0227] Western Blot test of the compounds of the present invention for the effects of the compounds on signaling pathways

[0228] (i) HaCaT cells in logarithmic growth phase were seeded in 6-well plates (3×10 5cells / well) and cultured overnight in a 5% CO2, 37°C incubator;

[0229] (ii) The supernatant was removed and DMEM complete medium containing 100 ng / mL TNF-α was added for stimulation for 24 h. Then the supernatant was removed and different drugs were added to different wells for treatment for 24 h.

[0230] (iii) Collect cells and wash three times with PBS, add high-strength RIPA lysis buffer to lyse cells and extract proteins, determine protein concentration by BCA method, and then separate equal amounts of protein (50μg) by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Use a membrane transfer instrument to transfer the protein to a PVDF membrane (7-15min) (fast transfer method), wash three times with TBST, then block with protein-free fast blocking solution for 30-60min, and wash three times with TBST. The membrane was then incubated with the primary antibody at 4°C overnight and washed three times with TBST. The membrane was then incubated with a chemical rabbit secondary antibody at room temperature for 2h, washed three times with TBST, and finally displayed by Odyssey infrared imaging (GAPDH as an internal reference).

[0231] Experimental results: The target molecules Z17j and Z17h can achieve dual inhibition of JAK and HDAC at the cellular level by regulating the JAK-STAT5 pathway and inhibiting the deacetylation of histones H3 and H4. Figure 1 and Figure 2 As shown, Figure 1 This is a schematic diagram of the results of Western Blot testing the effects of compounds Z17j and Z17h on acetylated H3 and H4.

[0232] Figure 2 This is a schematic diagram of the results of Western Blot testing the effects of compounds Z17j and Z17h on phosphorylated STAT5. The cells were treated with compounds Z17h and Z17j at concentrations of 0.9μM and 0.1μM for 24h, and the positive drugs SAHA and CYT387 at the same concentration were used as controls. Compounds Z17h and Z17j can increase the level of acetylated histone H3 in a dose-dependent manner; Z17j can increase the level of acetylated histone H4 in a dose-dependent manner, and Z17h has no significant effect on the expression of acetylated histone H4 even at a concentration of 0.9μM ( Figure 2 ).

[0233] At a concentration of 0.9 μM, compounds Z17j and Z17h both induced the downregulation of phosphorylated STAT5 ( Figure 2 ). These results further confirmed the inhibitory effects of compounds Z17h and Z17j on the intracellular JAK-STAT pathway.

[0234] In summary, the target molecules Z17j and Z17h can achieve dual inhibition of JAK and HDAC at the cellular level by regulating the JAK-STAT5 pathway and inhibiting the deacetylation of histones H3 and H4.

[0235] Embodiment 24

[0236] Experimental study on the effect of the compound of the present invention on the psoriasis mouse model induced by imiquimod

[0237] (1) Mouse strain: BALB / c mice (SPF grade), sex: male; body weight: 18-20 g; acclimatized to the environment for one week in advance.

[0238] (2) Preparation of cream (drug concentration is 0.5%). The mass percentages of the components of the cream are shown in Table 6:

[0239] Phase A: polyoxyethylene (2) stearyl alcohol ether, polyoxyethylene (21) stearyl alcohol ether, liquid paraffin, a mixture of cetyl alcohol and stearyl alcohol (the mass ratio of cetyl alcohol to stearyl alcohol is 3:7), ethyl hydroxybenzoate, glyceryl monostearate; heated to 80°C and maintained at 80°C;

[0240] Phase B: Slowly add glycerol into water and heat to 80°C while stirring continuously;

[0241] Under stirring conditions, phase A is slowly added into phase B. After the addition, a homogenizer is used to homogenize for 3 minutes. When the temperature drops to 60° C., the ground compound is added and stirred to obtain a cream.

[0242] Table 6

[0243]

[0244]

[0245] (3) Grouping (9 groups, n = 5): control, normal, Z17j (0.25%), Z17j (0.5%), Z17h (0.5%), tofacitinib (0.5%), CYT387 (0.5%), SAHA (0.5%), SAHA (0.5%) + CYT387 (0.5%);

[0246] (4) Formal experiment: Apply imiquimod cream (Aida Le, 250 mg: 12.5 mg) once a day, and apply the homemade cream at intervals of more than 4 hours. Observe the condition of the mice daily and record the weight of the mice. Continuously administer the medicine for 6 days until the model group is successfully established. After the experiment, the back skin of the mice was photographed, and the spleen was dissected and photographed. Then the back skin of the mice was taken out for HE staining experiments, mainly to measure the thickness of the epidermis of the mouse skin and take pictures.

[0247] The experimental results are as follows Figure 3 As shown, Figure 3 The figure is a schematic diagram of the results of the study of the anti-psoriasis activity of topical drugs (creams) of compounds Z17j and Z17h on the back skin of mice. The blank group (normal) is normal mouse skin, with smooth skin and no wrinkles. The back skin of mice in the control group showed obvious psoriasis, redness, swelling, scabs, and wrinkles. The comparison of the skin of these two groups of mice showed that the model was successfully established. The back skin of mice in the parent drug CYT387 (0.5%), SAHA (0.5%) and their combined control group CYT387 (0.5%) + SAHA (0.5%) group was the best, with no obvious psoriasis and scabs, relatively smooth skin, and only slight wrinkles; while the effect of SAHA was not as good as CYT387, and the SAHA (0.5%) group showed obvious wrinkles and slight psoriasis accompanied by scabs. Although Z17h also has a good effect (slight redness and swelling, no obvious psoriasis), it is comparable to the parent drug group (CYT387 (0.5%) + SAHA (0.5%) group), but slightly worse than Z17j (0.5%) and the marketed positive drug tofacitinib (0.5%) group, and Z17j (0.5%) is better than tofacitinib (0.5%). At the same time, the effect of Z17j (0.5%) compared with Z17j (0.25%) is also more obvious, preliminarily proving that the effect of Z17j is dose-dependent, and the higher the concentration, the better the effect, indicating that Z17j has the best anti-psoriasis effect, which is better than the two positive drugs and their combined administration.

[0248] The experimental results are as follows Figure 4 As shown, Figure 4 This is a schematic diagram of the anti-psoriasis activity study results of topical drugs (creams) of compounds Z17j and Z17h, where A is a HE staining of the back skin of mice; B is a graph of the surface thickness of the mouse skin. The HE staining results further confirmed the therapeutic effect of the JAK / HDAC dual-target inhibitor Z17j. Similar to the results observed with the naked eye, the surface thickness of the back skin of mice in the parent drug CYT387, SAHA and its combined control group CYT387+SAHA group was the thinnest in the CYT387 (0.5%) + SAHA (0.5%) group. The back skin of mice treated with Z17j was thinner than that of the CYT387 (0.5%) + SAHA (0.5%) group, and the effect was better. Compared with Z17h (0.5%), the skin of mice treated with Z17j (0.5%) was also thinner, the effect was better, and it was dose-dependent. Compared with tofacitinib (0.5%), Z17j (0.5%) also had a better effect. This indicates that Z17j has the best anti-psoriasis effect, which is superior to the two positive drugs and their combined administration.

[0249] The experimental results are as follows Figure 5 As shown, Figure 5 This is a schematic diagram of the mouse spleen results of the anti-psoriasis activity study of compound Z17j and Z17h topical medication (cream). Judging from the size of the spleen, the JAK / HDAC dual-target inhibitor Z17j (0.5% concentration) can significantly inhibit the enlargement of the spleen in mice, indicating that Z17j has the best anti-psoriasis effect, which is better than the two positive drugs and their combined administration, and has a certain anti-inflammatory effect.

[0250] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A compound having anti-psoriatic activity or a pharmaceutically acceptable salt thereof, It is characterized in that The general structural formula is shown below: Among them, R 1 Select one of the following structures: R 2 Select one of the following structures: R 3 Selected from OH, n1 is a positive integer selected from 0 to 10; n2 is a positive integer selected from 0 to 10; m1 is a positive integer selected from 0 to 20; m2 is a positive integer selected from 0 to 20; R 4 Selected from H, NH 2 , R 5 Selected from H, NH 2 , R 6 Selected from H, NH 2 , R 7 Selected from H, NH 2 , R 8 Selected from H, NH 2 , R 9 Selected from H, C1-C20 alkyl; R 10 Selected from H, C1-C20 alkyl.

2. The compound having anti-psoriatic activity according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that In the compound having anti-psoriasis activity, R 1 Select one of the following structures: R 2 Select one of the following structures:

3. The compound having anti-psoriatic activity according to claim 2 or a pharmaceutically acceptable salt thereof, It is characterized in that The compound having anti-psoriatic activity is selected from one of the following structures:

4. Use of a compound having anti-psoriatic activity or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of an anti-psoriatic drug.

5. Use of a compound having anti-psoriasis activity or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of an anti-inflammatory drug.

6. Use of the compound having anti-psoriatic activity or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of a JAK / HDAC dual-target inhibitor.

Citation Information

Cited By

  • Application of vorinostat in preparation of external skin preparation for treating psoriasis

    CN119454674A